

same [type], [said vehicle being capable of suspending beneficial agents and homogeneously dispensing said beneficial agent over an extended period of time at body temperature and at low flow rates] and wherein the viscosity of the vehicle is between about 1,000 and about 10,000,000 poise.

3. [Twice Amended] A stable non-aqueous single phase biocompatible viscous vehicle comprising at least two components selected from the group consisting of solvent, surfactant, and polymer, wherein the components are not [of] the same [type], [said vehicle being capable of suspending beneficial agents and homogeneously dispensing said beneficial agent over an extended period of time at body temperature and at low flow rates] and wherein the viscosity of the vehicle is between about 1,000 and about 10,000,000 poise.

4. [Twice Amended] A stable non-aqueous single phase biocompatible viscous vehicle which comprises three components selected from the group consisting of solvent, surfactant, and polymer, wherein the components are not [of] the same [type], [said vehicle being capable of suspending beneficial agents and homogeneously dispensing said beneficial agent over an extended period of time at body temperature and at low flow rates] and wherein the viscosity of the vehicle is between about 1,000 and about 10,000,000 poise.

10. [Amended] The vehicle of claim 4 wherein the polymer is polyvinylpyrrolidone, the surfactant is [gml] glycerol monolaurate, and the solvent is lauryl lactate.

13. [Amended] The vehicle of claim 4 wherein the polymer is poly(D,L-Lactide), the surfactant is a [Pluronic] polyoxyethylenepolyoxypropylene block copolymer, and the solvent is propylene carbonate.

17. [Twice Amended] A stable non-aqueous viscous protein formulation comprising
- a) at least one beneficial agent, and
 - b) a non-aqueous single phase biocompatible viscous vehicle comprising two components selected from the group consisting of solvent, surfactant, and polymer, wherein the two components are not [of] the same [type] and wherein the viscosity of the vehicle is between about 1,000 and about 10,000,000 poise, which formulation is capable of being uniformly dispensed over an extended period of time at a low flow rate.
18. [Twice Amended] A non-aqueous formulation comprising at least one beneficial agent uniformly suspended in a non-aqueous single phase biocompatible viscous vehicle comprising two components selected from the group consisting of solvent, surfactant, and polymer, wherein the two components are not [of] the same [type] and wherein the viscosity of the vehicle is between about 1,000 and about 10,000,000 poise, which formulation can be delivered from an implantable drug delivery system such that the exit shear rate of the formulation is between about 1 and 1×10^{-7} reciprocal second.
33. [Twice Amended] A method for preparing the stable formulation of claim 17[, 41, or 42] comprising combining the single phase viscous vehicle and beneficial agent under dry conditions and blending them under vacuum at elevated temperature to uniformly [disperse] suspend the beneficial agent in the vehicle, and allowing the formulation to cool to room temperature.
42. [Amended] A stable non-aqueous viscous protein formulation comprising
- a) at least one beneficial agent, and

b) a non-aqueous single phase biocompatible viscous vehicle comprising at least two components selected from the group consisting of solvent, surfactant, and polymer, wherein the components are not [of] the same [type] and wherein the viscosity of the vehicle is between about 1,000 and about 10,000,000 poise, [wherein the components are not of the same type,] which formulation is capable of being uniformly dispensed over an extended period of time at a low flow rate.

43. [Amended] A stable non-aqueous viscous protein formulation comprising

- a) at least one beneficial agent, and
- b) a non-aqueous single phase biocompatible viscous vehicle which comprises three components selected from the group consisting of solvent, surfactant, and polymer, wherein the components are not [of] the same [type] and wherein the viscosity of the vehicle is between about 1,000 and about 10,000,000 poise, which formulation is capable of being uniformly dispensed over an extended period of time at a low flow rate.

44. [Amended] A non-aqueous formulation comprising at least one beneficial agent uniformly suspended in a non-aqueous single phase biocompatible viscous vehicle comprising at least two components selected from the group consisting of solvent, surfactant, and polymer, wherein the components are not [of] the same [type] and wherein the viscosity of the vehicle is between about 1,000 and about 10,000,000 poise, which formulation can be delivered from an implantable drug delivery system such that the exit shear rate of the formulation is between about 1 and 1×10^{-7} reciprocal second.

45. [Amended] A non-aqueous formulation comprising at least one beneficial agent uniformly suspended in a non-aqueous single phase biocompatible viscous vehicle which comprises three components selected from the group consisting of